FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age
Go back to FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 466.79 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $466.79 | 52 Week High | $134.71 | |||
| Open | $466.79 | 52 Week Low | $73.31 | |||
| Day High | $466.79 | P/E | N/A | |||
| Day Low | $466.79 | EPS | $-1.98 | |||
| Volume | 2,345 | |||||
